Puma Biotechnology (NASDAQ:PBYI) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Puma Biotechnology (NASDAQ:PBYI) in a research report sent to investors on Monday,Benzinga reports. HC Wainwright currently has a $7.00 target price on the biopharmaceutical company’s stock.

Separately, StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 6th.

Puma Biotechnology Price Performance

Shares of Puma Biotechnology stock opened at $3.02 on Monday. Puma Biotechnology has a twelve month low of $2.22 and a twelve month high of $7.73. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42. The firm has a market cap of $148.25 million, a P/E ratio of 6.29 and a beta of 1.08. The firm’s 50-day simple moving average is $2.95 and its 200-day simple moving average is $2.99.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The company had revenue of $80.50 million for the quarter, compared to the consensus estimate of $71.32 million. During the same period in the previous year, the business earned $0.12 earnings per share. As a group, research analysts expect that Puma Biotechnology will post 0.31 EPS for the current fiscal year.

Institutional Trading of Puma Biotechnology

Several large investors have recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC bought a new position in shares of Puma Biotechnology in the third quarter valued at approximately $627,000. FMR LLC raised its position in Puma Biotechnology by 27.1% in the 3rd quarter. FMR LLC now owns 118,265 shares of the biopharmaceutical company’s stock valued at $302,000 after purchasing an additional 25,183 shares during the last quarter. Affinity Asset Advisors LLC acquired a new position in Puma Biotechnology in the second quarter worth $815,000. Frazier Life Sciences Management L.P. grew its holdings in shares of Puma Biotechnology by 8.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock worth $9,984,000 after purchasing an additional 246,264 shares during the last quarter. Finally, American Century Companies Inc. increased its stake in shares of Puma Biotechnology by 98.5% in the second quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock valued at $2,409,000 after buying an additional 366,653 shares in the last quarter. 61.29% of the stock is owned by institutional investors.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.